Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2009-05-22
2010-11-16
Mertz, Prema (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C536S023530, C435S252300, C435S320100, C435S325000
Reexamination Certificate
active
07833755
ABSTRACT:
Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
REFERENCES:
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5210075 (1993-05-01), Scholz et al.
patent: 5326859 (1994-07-01), Sugano et al.
patent: 5468609 (1995-11-01), Revel et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5554513 (1996-09-01), Revel et al.
patent: 5559012 (1996-09-01), Brailly et al.
patent: 5591827 (1997-01-01), Brakenhoff et al.
patent: 5618700 (1997-04-01), Novick et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5639455 (1997-06-01), Shimamura et al.
patent: 5723120 (1998-03-01), Brakenhoff et al.
patent: 5738931 (1998-04-01), Sato et al.
patent: 5789552 (1998-08-01), Savino et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5817790 (1998-10-01), Tsuchiya et al.
patent: 5849283 (1998-12-01), Ciliberto
patent: 5854398 (1998-12-01), Chang et al.
patent: 5856135 (1999-01-01), Tsuchiya et al.
patent: 5871723 (1999-02-01), Strieter et al.
patent: 5888510 (1999-03-01), Kishimoto et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5914106 (1999-06-01), Ciliberto
patent: 5942220 (1999-08-01), Warren et al.
patent: 5958400 (1999-09-01), Ruben et al.
patent: 5972902 (1999-10-01), Ciliberto
patent: 6010864 (2000-01-01), Hoeprich, Jr.
patent: 6086874 (2000-07-01), Yoshida et al.
patent: 6121423 (2000-09-01), Tsuchiya et al.
patent: 6261560 (2001-07-01), Tsujinaka et al.
patent: 6461604 (2002-10-01), Somers et al.
patent: 6482411 (2002-11-01), Ahuja et al.
patent: 7291721 (2007-11-01), Giles-Komar et al.
patent: 2001/0001663 (2001-05-01), Kishimoto et al.
patent: 2003/0190316 (2003-10-01), Kakuta et al.
patent: 2004/0028681 (2004-02-01), Ito et al.
patent: 0399429 (1990-11-01), None
patent: 0572118 (1993-04-01), None
patent: 0617126 (1994-09-01), None
patent: 800829 (1997-10-01), None
patent: WO 91/08774 (1991-06-01), None
patent: WO 94/09138 (1994-04-01), None
patent: WO 95/03036 (1995-02-01), None
patent: WO 01/58956 (2001-08-01), None
patent: WO 03/083061 (2003-10-01), None
patent: WO 2004/039826 (2004-05-01), None
patent: WO 2004/096273 (2004-11-01), None
patent: WO 2005/005604 (2005-01-01), None
patent: WO 2005/028514 (2005-03-01), None
US 6,008,005, 12/1999, Shiraki et al. (withdrawn)
Brakenhoff, et al., “Structure-Function Analysis of Human IL-6 Epitope Mapping of Neutralizing Monoclonal Antibodies with Amino-and Carboxyl-Terminal Deletion Mutants,” The Journal of Immunology, 145(2): 561-568 (1990).
Brakenhoff, et al., “Molecular Cloning and Expression of Hybridoma Growth Factor inEscherichia coli,” The Journal of Immunology, 139(12): 4116-4121 (1987).
Van Zaanen, et al., Blocking Interleukin-6 Activity with Chimeric Anti-IL6 Monoclonal Antibodies in Multiple Myeloma: Effects on Soluble IL6 Receptor and Soluble gp 130, Leukemia & Lymphoma, 31(5-6): 551-558 (1998).
Van Zaanen, et al., Endogenous Interleukin 6 Production in Multiple Myeloma Patients Treated with Chimeric Monoclonal Anti-IL6 Antibodies Indicates the Existence of a Positive Feed-back Loop, Journal of Clinical Investigations, The American Society for Clinical Investigation, Inc., 98(6): 1441-1448 (1996).
Van Oers, Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a Phase I dose-escalating study, British Journal of Haematology, 102(3): 783-790 (1998).
Baselga, et al., “Receptor Blockage with Monoclonal Antibodies as Anti-Cancer Therapy,” Pharmaceutical Therapy, 64: 127-154 (1994).
Matsuda, et al., “Establishment of an interleukin 6 (IL6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies,” European Journal of Immunology, 18: 951-956 (1988).
Seideman, et al., “A novel monoclonal antibody screening method using the Luminex-100 microsphere system,” Journal of Immunology Methods, 267: 165-171 (2002).
Bataille, et al., Biologica Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma, Blood, 86(2): 685-691 (1995).
Trikha, et al., “Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence,” Clinical Cancer Res., 9: 4653-4665 (2003).
Sato, et al., “Humanization of an Anti-Human IL-6 Mouse Monoclonal Antibody Glycosylated in its Heavy Chain Variable Region,” Human Antibodies and Hybridomas, 7(4): 175-183 (1996).
Naka, et al., “The Paradigm of IL-6: From Basic Science to Medicine,” Arthritis Research, Current Science, 4(3): S233-S242 (2002).
Petrov, “Immunology,” Medicine Publishers, 56-58 (1987), Russian Article and English translation.
Paul, “Fv Structure and Diversity in Three Dimensions,” Fundamental Immunology, 3rdedition pp. 292-295 (1993).
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Science, USA 79: 1979-1783 (1982).
Cruse and Lewis, Illustrated Dictionary of Immunology, p. 19 (1995).
Aoki, et al., “Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6,” Blood, 93(12): 4034-4043 (1999).
Pourtau, et al., “Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin M,” FEBS Letters, 459: 453-457 (1999).
Wei, et al., “Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway,” Oncogene, 22:1517-1527 (2003).
Motro, et al., “Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis,” Proceedings of the National Academy of Science USA, 87: 3092-3096 (1990).
Cohen, et al., “Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor,” The Journal of Biological Chemistry, 271(2): 736-741 (1996).
Chauhan, et al., “SHP2 Mediates the Protective Effect of Interleukin-6 against Dexamethasone-induced Apoptosis in Multiple Myeloma Cells,” The Journal of Biological Chemistry, 275(36): 27845-27850 (2000).
Blay, et al., “Serum Level of Interleukin 6 as a Prognosis Factor in Metastic Renal Cell Carcinoma,” Cancer Research, 52: 3317-3322 (1992).
Miki, et al., “Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas,” FEBS Letters, 250(2): 607-610 (1989).
Vink, et al., Mouse Plasmacytoma Growth In Vivo: Enhancement by Interleukin 6 (IL-6) and Inhibition by Antibodies Directed against IL-6 or Its Receptor, Journal of Experimental Medicine, 172: 997-1000 (1990).
Sato, et al., “Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth,” Cancer Research, 53: 851-856 (1993).
Shimamura, et al., “Analysis of Interleukin-6 (IL-6)/IL-6 Receptor System Using Monoclonal Anti-IL-6 Antibodies,” Molecular Immunology, 28(11): 1155-1161 (1991).
Chen Yan
Gardner Debra
Knight David M.
Lark Michael W.
Liang Bailin
Dichter Eric
Mertz Prema
LandOfFree
Anti-IL-6 antibody nucleic acid molecules and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL-6 antibody nucleic acid molecules and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-6 antibody nucleic acid molecules and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237321